Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.

Zhonggu Logistics has filed for a $218m on the Shanghai Stock Exchange, providing exits to Zhonggu Shipping and SoftBank.

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.